- Q3 revenue $205.9 million vs $213.7 million a year ago.
- Full-year net sales guidance lowered to ~$900 million from $910 million.
Usana Health Sciences cut its full-year guidance and reported lower third-quarter revenue. Shares dropped 10% in after-hours trading.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.